UNSPSC 51313110: Buclizine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C28H33ClN2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 58FQD093NU, chemically known as piperazine, 1-(p-tert-butylbenzyl)-4-(p-chloro-.alpha.-phenylbenzyl)-, dihydrochloride but more generally known as buclizine hydrochloride, which bears US NIH Compound Identifier 6729. European Medicines Agency schedules Buclizine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00889MIG.

UNSPSC 51313110 Buclizine hydrochloride is a Commodity code that in practice encompasses a much broader range of pharmaceutical and over-the-counter products than its specific drug name suggests. State and local governments soliciting under this code are procuring generic multi-source pharmaceuticals, OTC medications, and specialized health-related products such as naloxone and drug deactivation systems for community health and emergency response initiatives. The issuing bodies include state health and human services departments, county health departments, and cooperative purchasing alliances serving multiple jurisdictions. Scope varies from routine pharmaceutical supply agreements requiring compliance with FDA manufacturing standards and drug supply chain security regulations to specialized procurement for opioid response and harm-reduction initiatives.

Recent activity shows issuing bodies across Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with proposals due March 26, 2026 and contract awards effective July 1, 2026. Vendors responding to these solicitations must demonstrate FDA compliance, cGMP certification, drug supply chain security adherence, and capacity to integrate with state procurement systems and authorized distribution channels.